ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression
Hepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer with limited treatment options and extremely poor prognosis worldwide. Recently, the proteolysis targeting chimeras (PROTACs), which aim to induce proteasome-mediated degradation of interesting proteins via recruiting E3 liga...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.858901/full |
| _version_ | 1811231001325600768 |
|---|---|
| author | Yuanfei Deng Cuifu Yu Lushi Chen Xin Zhang Qiucheng Lei Qing Liu Gengxi Cai Fang Liu |
| author_facet | Yuanfei Deng Cuifu Yu Lushi Chen Xin Zhang Qiucheng Lei Qing Liu Gengxi Cai Fang Liu |
| author_sort | Yuanfei Deng |
| collection | DOAJ |
| description | Hepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer with limited treatment options and extremely poor prognosis worldwide. Recently, the proteolysis targeting chimeras (PROTACs), which aim to induce proteasome-mediated degradation of interesting proteins via recruiting E3 ligases, have become the advanced tools and attractive molecules for cancer treatment. However, the anticancer effects of PROTACs in HCC remain to be clarified. Here, we evaluate the anticancer activity of ARV-771, a previously reported PROTAC compound designed for bromodomain and extra-terminal domain (BET) proteins, in HCC. We show that ARV-771 suppresses the cell viability and colony formation of HCC cells via arresting cell cycle progression and triggering apoptosis. Further investigations reveal that ARV-771 notably downregulates multiple non-proteasomal deubiquitinases which are critical to the development of cancers. Additionally, HCC cells can decrease their sensitivity to ARV-771 via activating the MEK/ERK and p38 MAPKs. ARV-771 also inhibits HCC progression in vivo. Moreover, we show that ARV-771 and sorafenib, a Raf inhibitor that clinically used for targeted therapy of liver cancer, can synergistically inhibit the growth of HCC cells. Overall, this study not only explores the anticancer activity of ARV-771 and its underlying mechanisms in HCC, but also deepens our understanding of deubiquitinases, MAPKs, cell cycle, and apoptosis induction in cancer therapy. |
| first_indexed | 2024-04-12T10:37:49Z |
| format | Article |
| id | doaj.art-1013ef9a6aa9461fa6aa13dea4fb300a |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-12T10:37:49Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-1013ef9a6aa9461fa6aa13dea4fb300a2022-12-22T03:36:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-05-011310.3389/fphar.2022.858901858901ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma ProgressionYuanfei Deng0Cuifu Yu1Lushi Chen2Xin Zhang3Qiucheng Lei4Qing Liu5Gengxi Cai6Fang Liu7Department of Pathology, The First People’s Hospital of Foshan, Foshan, ChinaGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaHealth Management Center, The First People’s Hospital of Foshan, Foshan, ChinaDepartment of Pathology, The First People’s Hospital of Foshan, Foshan, ChinaDepartment of Hepatopancreatic Surgery, The First People’s Hospital of Foshan, Foshan, ChinaDepartment of Pathology, The First People’s Hospital of Foshan, Foshan, ChinaDepartment of Breast Surgery, The First People’s Hospital of Foshan, Foshan, ChinaDepartment of Pathology, The First People’s Hospital of Foshan, Foshan, ChinaHepatocellular carcinoma (HCC) is the most commonly diagnosed liver cancer with limited treatment options and extremely poor prognosis worldwide. Recently, the proteolysis targeting chimeras (PROTACs), which aim to induce proteasome-mediated degradation of interesting proteins via recruiting E3 ligases, have become the advanced tools and attractive molecules for cancer treatment. However, the anticancer effects of PROTACs in HCC remain to be clarified. Here, we evaluate the anticancer activity of ARV-771, a previously reported PROTAC compound designed for bromodomain and extra-terminal domain (BET) proteins, in HCC. We show that ARV-771 suppresses the cell viability and colony formation of HCC cells via arresting cell cycle progression and triggering apoptosis. Further investigations reveal that ARV-771 notably downregulates multiple non-proteasomal deubiquitinases which are critical to the development of cancers. Additionally, HCC cells can decrease their sensitivity to ARV-771 via activating the MEK/ERK and p38 MAPKs. ARV-771 also inhibits HCC progression in vivo. Moreover, we show that ARV-771 and sorafenib, a Raf inhibitor that clinically used for targeted therapy of liver cancer, can synergistically inhibit the growth of HCC cells. Overall, this study not only explores the anticancer activity of ARV-771 and its underlying mechanisms in HCC, but also deepens our understanding of deubiquitinases, MAPKs, cell cycle, and apoptosis induction in cancer therapy.https://www.frontiersin.org/articles/10.3389/fphar.2022.858901/fullhepatocellular carcinomaPROTACsARV-771deubiquitinasesMAPKs |
| spellingShingle | Yuanfei Deng Cuifu Yu Lushi Chen Xin Zhang Qiucheng Lei Qing Liu Gengxi Cai Fang Liu ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression Frontiers in Pharmacology hepatocellular carcinoma PROTACs ARV-771 deubiquitinases MAPKs |
| title | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
| title_full | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
| title_fullStr | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
| title_full_unstemmed | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
| title_short | ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression |
| title_sort | arv 771 acts as an inducer of cell cycle arrest and apoptosis to suppress hepatocellular carcinoma progression |
| topic | hepatocellular carcinoma PROTACs ARV-771 deubiquitinases MAPKs |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.858901/full |
| work_keys_str_mv | AT yuanfeideng arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT cuifuyu arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT lushichen arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT xinzhang arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT qiuchenglei arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT qingliu arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT gengxicai arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression AT fangliu arv771actsasaninducerofcellcyclearrestandapoptosistosuppresshepatocellularcarcinomaprogression |